Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping

Gordon F. Schwartz; Harry Bartelink; Harold J. Burstein; Blake Cady; Luigi Cataliotti; Ian S. Fentiman; Roland Holland; Kevin S. Hughes; Shahla Masood; Beryl McCormick; Juan A. Palazzo; Peter I. Pressman; Jorge Reis-Filho; Lajos Pusztai; Emiel J.T. Rutgers; Andrew D. Seidman; Lawrence J. Solin; Joseph A. Sparano

doi:10.1111/j.1524-4741.2012.01264.x

Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping

Gordon F. Schwartz, Harry Bartelink, Harold J. Burstein, Blake Cady, Luigi Cataliotti, Ian S. Fentiman, Roland Holland, Kevin S. Hughes, Shahla Masood, Beryl McCormick, Juan A. Palazzo, Peter I. Pressman, Jorge Reis-Filho, Lajos Pusztai, Emiel J.T. Rutgers, Andrew D. Seidman, Lawrence J. Solin, Joseph A. Sparano

Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

Original language	English (US)
Pages (from-to)	303-311
Number of pages	9
Journal	Breast Journal
Volume	18
Issue number	4
DOIs	https://doi.org/10.1111/j.1524-4741.2012.01264.x
State	Published - Jul 2012

Keywords

Her-2-neu
Ki-67
adjuvant therapy
breast carcinoma
estrogen receptors
gene analysis
progesterone receptors

ASJC Scopus subject areas

Internal Medicine
Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1524-4741.2012.01264.x

Cite this

Schwartz, G. F., Bartelink, H., Burstein, H. J., Cady, B., Cataliotti, L., Fentiman, I. S., Holland, R., Hughes, K. S., Masood, S., McCormick, B., Palazzo, J. A., Pressman, P. I., Reis-Filho, J., Pusztai, L., Rutgers, E. J. T., Seidman, A. D., Solin, L. J., & Sparano, J. A. (2012). Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping. Breast Journal, 18(4), 303-311. https://doi.org/10.1111/j.1524-4741.2012.01264.x

Schwartz, GF, Bartelink, H, Burstein, HJ, Cady, B, Cataliotti, L, Fentiman, IS, Holland, R, Hughes, KS, Masood, S, McCormick, B, Palazzo, JA, Pressman, PI, Reis-Filho, J, Pusztai, L, Rutgers, EJT, Seidman, AD, Solin, LJ & Sparano, JA 2012, 'Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping', Breast Journal, vol. 18, no. 4, pp. 303-311. https://doi.org/10.1111/j.1524-4741.2012.01264.x

@article{434da6044a4141de9253724a73140866,

title = "Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping",

abstract = "A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.",

keywords = "Her-2-neu, Ki-67, adjuvant therapy, breast carcinoma, estrogen receptors, gene analysis, progesterone receptors",

author = "Schwartz, {Gordon F.} and Harry Bartelink and Burstein, {Harold J.} and Blake Cady and Luigi Cataliotti and Fentiman, {Ian S.} and Roland Holland and Hughes, {Kevin S.} and Shahla Masood and Beryl McCormick and Palazzo, {Juan A.} and Pressman, {Peter I.} and Jorge Reis-Filho and Lajos Pusztai and Rutgers, {Emiel J.T.} and Seidman, {Andrew D.} and Solin, {Lawrence J.} and Sparano, {Joseph A.}",

year = "2012",

month = jul,

doi = "10.1111/j.1524-4741.2012.01264.x",

language = "English (US)",

volume = "18",

pages = "303--311",

journal = "Breast Journal",

issn = "1075-122X",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Adjuvant therapy in Stage i carcinoma of the breast

T2 - The influence of multigene analyses and molecular phenotyping

AU - Schwartz, Gordon F.

AU - Bartelink, Harry

AU - Burstein, Harold J.

AU - Cady, Blake

AU - Cataliotti, Luigi

AU - Fentiman, Ian S.

AU - Holland, Roland

AU - Hughes, Kevin S.

AU - Masood, Shahla

AU - McCormick, Beryl

AU - Palazzo, Juan A.

AU - Pressman, Peter I.

AU - Reis-Filho, Jorge

AU - Pusztai, Lajos

AU - Rutgers, Emiel J.T.

AU - Seidman, Andrew D.

AU - Solin, Lawrence J.

AU - Sparano, Joseph A.

PY - 2012/7

Y1 - 2012/7

N2 - A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

AB - A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

KW - Her-2-neu

KW - Ki-67

KW - adjuvant therapy

KW - breast carcinoma

KW - estrogen receptors

KW - gene analysis

KW - progesterone receptors

UR - http://www.scopus.com/inward/record.url?scp=84863646635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863646635&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4741.2012.01264.x

DO - 10.1111/j.1524-4741.2012.01264.x

M3 - Article

C2 - 22759093

AN - SCOPUS:84863646635

SN - 1075-122X

VL - 18

SP - 303

EP - 311

JO - Breast Journal

JF - Breast Journal

IS - 4

ER -

Adjuvant therapy in Stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this